Cardiol Therapeutics Inc. Class A · TSX:CRDL
Cardiol Therapeutics Inc. Class A — Investor Presentation (May 2023)
30 slides from Cardiol Therapeutics Inc. Class A's investor presentation, May 2023
Slide 1: Heal the heart with innovative science
Corporate Presentation Heal the heart with innovative science We are a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease Cardiolrx.com TSX: CRDL May 2023 NASDAQ: CRDL
Slide 2: Disclaimer
Disclaimer In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Any graphs, tables or other information in this presentation demonstrating the historical performance of Cardiol Therapeutics Inc. (“Cardiol”) or any other entity contained in this presentation are inte
Slide 3: Developing Novel Therapeutic
Developing Novel Lead Asset in Clinical Development Broad Exclusivity Protection Therapeutic CardiolRx™, oral drug candidate, in Phase II trials for recurrent pericarditis and acute myocarditis. Comprehensive intellectual property portfolio. Eligible to pursue FDA orphan drug and EMA Approaches for
Slide 4: Product Pipeline
Product Pipeline Drug Candidate Pre-Clinical Phase I Phase II Phase III Developing drug candidates CardiolRx™ that attenuate multiple Recurrent Pericarditis inflammatory signaling pathways, including inhibiting activation of the NLRP3 Acute Myocarditis inflammasome, known to play an important role i
Slide 5: Major Milestones
Major Milestones Next 12 – 24 months 1 Complete Phase II U.S. study in recurrent pericarditis with 2 Complete patient enrollment in the global ARCHER trial 3 Advance development of a subcutaneously administered formulation CardiolRx™ in acute myocarditis intended for use in with CardiolRx™ heart fai
Slide 6: Key Global Research and Clinical Collaborators
Key Global Research and Clinical Collaborators Working together with world-class researchers and clinicians at international centers of excellence and leveraging their expertise in drug development, experimental execution, inflammation and fibrosis, the treatment of cardiovascular diseases, and clin
Slide 7: Recurrent Pericarditis
Recurrent Pericarditis Phase II study to evaluate the tolerability, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis. NASDAQ: CRDL | TSX: CRDL May 2023 7
Slide 8: Recurrent Pericarditis
Recurrent Pericarditis • Pericarditis refers to inflammation of the pericardium (the membrane, or sac, surrounding the heart) that leads to fluid accumulation (effusion) and pericardial thickening. • Recurrent pericarditis is the reappearance of symptoms after a symptom-free period of at least 4 – 6
Slide 9: CardiolRx for Recurrent Pericarditis
CardiolRx™ for Recurrent Pericarditis Phase II Clinical Development Program Multi-center, open-label pilot study to assess the Primary Efficacy Endpoint safety and tolerability of CardiolRx™ during the • Change, from baseline to 8 weeks, in patient- resolution of a pericarditis recurrence, evaluate
Slide 10: Advisors and Key Investigators for Recurrent Pericarditis Phase II Study
Advisors and Key Investigators for Recurrent Pericarditis Phase II Study Allan Klein, MD, CM Paul Cremer, MD Study Chair Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart, Vascular and Director, Center for the Diagnosis and Treatment of Peric
Slide 11: Recurrent Pericarditis: Market Opportunity
Recurrent Pericarditis: Market Current Pharmacotherapy • First-line conventional treatment: NSAIDs or aspirin with or without colchicine(1). Opportunity • Second-line therapy for patients with continued recurrence and inadequate response: corticosteroids (despite safety issues and difficulty taperin
Slide 12: Significant Reduction of IL-1β and IL-6 Pre-Clinically
Significant IL-1β Pro IL-1β IL-1ßmRNA Reduction of Pro mRNA IL-1ß 600 ✱✱✱ ✱✱✱ ✱ 1600 ✱✱✱ Fold increase vs control Multiple in vitro ✱✱✱ 1400 ✱✱✱ ✱✱✱ 1200 400 *P<0.05 1000 ***P<0.001 ***P<0.001 Parameters pg/ml 800 600 200 400 Demonstrated 200 0 0 CONTROL LPS LPS+CBD 1 10 TP L 01 Pre-clinically 1 0.
Slide 13: Significant Reduction in Pericardial Effusion & Thickness
Significant Reduction in Pericardial Pericardial Space Pericardial Thickness Zymosan A Effusion & Pericardial Thickness Demonstrated Zymosan A + CBD 10 mg/kg in vivo Pre-clinically Pericardial thickness of heart sections stained with hematoxylin and eosin. Martinez-Naya N et al. Circ Res 2022; 131:e
Slide 14: ARCHER Trial
ARCHER Trial Phase II study of CardiolRx™ in patients with acute myocarditis. NASDAQ: CRDL | TSX: CRDL May 2023 14
Slide 15: Acute Myocarditis
Acute Myocarditis • Inflammatory condition of the heart muscle (myocardium) often resulting from viral infection. • Characterized by chest pain, impaired heart function, arrythmias, and conduction disturbances. • An important cause of acute and fulminant heart failure in young adults and a leading c
Slide 16: CardiolRx for Acute Myocarditis
CardiolRx™ for Acute Myocarditis Phase II ARCHER Trial Multi-national, double-blind, randomized, placebo- controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery in patients presenting with Primary Efficacy Endpoints* acute myocardit
Slide 17: Steering Committee for ARCHER Trial
Steering Committee for ARCHER Trial Dennis M. McNamara, MD Leslie T. Cooper, Jr., MD Chair Co-Chair Professor of Medicine at the University of Pittsburgh. He is also the Director of the General cardiologist and the Chair of the Mayo Clinic Enterprise Department of Heart Failure/Transplantation Progr
Slide 18: Acute Myocarditis: Market Opportunity
Acute Myocarditis: Current Pharmacotherapy • No FDA-approved therapies for acute myocarditis. Market • Management: guideline directed therapy for heart failure and arrythmia (e.g., β-blockers, Opportunity ACE-I, ARBs, inotropes, diuretics). • Goal: decrease cardiac workload, reduce congestion and im
Slide 19: Cannabidiol Attenuates Myocarditis-induced Fibrosis
Cannabidiol Attenuates Myocarditis-induced Fibrosis Effect of Cannabidiol on Heart Fibrosis Sections of Heart Tissue – Fibrosis Healthy Tissue Myocarditis Myocarditis + CBD Representative images of Sirius red-stained LV myocardium sections. Magnification: 100x. Lee W-S et al. (2016). Mol. Med. 22, 1
Slide 20: Heart Failure
Heart Failure CRD-38 is a novel proprietary subcutaneously administered drug formulation of cannabidiol intended for use in heart failure NASDAQ: CRDL | TSX: CRDL May 2023 20
Slide 21: Heart Failure
Heart Failure • A complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. • Patients experience shortness of breath, rapid heart rate, and edema, resulting in reduced exercise capacity, limitations undert
Slide 22: Types of Heart Failure
Types of Heart Failure • Systolic heart failure, also referred to as heart failure with reduced ejection fraction (HFrEF), occurs when the heart loses its ability to contract normally and is unable to pump with sufficient force to push enough blood into circulation. • Diastolic heart failure, also r
Slide 23: Heart Failure: Market Opportunity
Heart Failure: Market Current Pharmacotherapy Opportunity • Treatment goals: improve symptoms, patient clinical status, functional capacity, and quality of life; prevent hospitalizations; reduce mortality. o HFrEF (systolic): guideline directed therapy includes four core medication classes – RAS Unm
Slide 24: Cardioprotective Properties of Subcutaneous Cannabidiol Formulation
Cardioprotective Properties of Subcutaneous Cannabidiol Formulation Demonstrated in a Non-ischemic Model of Heart Failure Measurements of BNP mRNA expression in heart tissue Heart Sections Stained with Masson’s Trichome CONTROL ANGIOTENSIN II 5 *** BNP mRNA BNP/GAPDH 4 (fold change) # 3 2 ANGII + CB
Slide 25: Cannabidiol Inhibits and Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis
Cannabidiol Inhibits and also Promotes Reversal of Mechanisms leading to Cardiac Fibrosis in a Dose Dependent Manner Protects cardiac function and exhibits an anti-fibrotic effect, possibly mediated by endothelial-to-mesenchymal transition (“EndoMT”) Immunoflourescence (IF) images of HUVEC cells Top
Slide 26: Management Team
Management Team David Elsley, MBA Andrew Hamer, MBChB President and Chief Executive Officer Chief Medical Officer and Head of Research & Development Founder and former President and CEO of Vasogen Inc. More than 30 years’ Thirty years of global life sciences industry, medical affairs, and cardiology
Slide 27: Board of Directors
Board of Directors Guillermo Torre-Amione, MD, PhD David Elsley, MBA Chairman President and Chief Executive Officer Professor of Cardiology at the Methodist Hospital Research Institute, Professor of Founder and former President and CEO of Vasogen Inc. More than 30 years’ Medicine at the Weill Cornel
Slide 28: Scientific Advisory Board
Scientific Advisory Board Dr. Paul M. Ridker, MD, MPH Dr. Bruce McManus, PhD, MD Dr. Joseph A. Hill, MD, PhD Senior Advisor Senior Advisor Senior Advisor Director of the Center for Cardiovascular Disease Professor Emeritus, Department of Pathology and Professor of Internal Medicine and Molecular Bio
Slide 29: Developing Novel Therapeutic
Developing Novel Lead Asset in Clinical Development Broad Exclusivity Protection Therapeutic CardiolRx™, oral drug candidate, in Phase II trials for recurrent pericarditis and acute myocarditis. Comprehensive intellectual property portfolio. Eligible to pursue FDA orphan drug and EMA Approaches for
Slide 30: Cardiol Therapeutics Inc. Contact
Cardiol Therapeutics Inc. +1 289.910.0850 NASDAQ: CRDL Oakville, Cardiolrx.com Investor.relations@cardiolrx.com TSX: CRDL Ontario
Cardiol Therapeutics — Investor Presentation (May 2023) on 6ix